p.127 抽出テキスト

Clin Oncol 2018;48:542‒7 2) Inoue S, Saito Y, Tsuneto S, et al. A randomized, double‒blind study of hydromorphone hydrochloride extended‒release tablets versus oxycodone hydrochloride extended‒release tablets for cancer pain:efficacy and safety in Japanese cancer patients(EXHEAL:a Phase III study of EXtended‒release HydromorphonE for cAncer pain reLief). J Pain Res 2017;10:1953‒62 3) Yu S, Shen W, Yu L, et al. Safety and efficacy of once‒daily hydromorphone extended‒release versus twice‒daily oxycodone hydrochloride controlled‒release in chinese patients with cancer pain:a phase 3, randomized, double‒blind, multicenter study. J Pain 2014;15:835‒44 4) Hanna M, Thipphawong J;118 Study Group. A randomized, double‒blind comparison of OROS

(R)hydromorphone and controlled‒release morphine for the control of chronic cancer pain. BMC Palliat Care 2008;7:17 5) Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled‒release oxycodone formulation and controlled‒release hydromorphone in the treatment of cancer pain. Cancer 1997;79:1428‒37 6) Moriarty M, McDonald CJ, Miller AJ. A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. J Clin Res 1999;2:1‒8 7) Wirz S, Wartenberg HC, Nadstawek J. Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open‒labeled investigation on cancer pain. Support Care Cancer 2008;16:999‒1009 8) Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy:a

prospective comparison of oral sustained‒release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009;13:737‒43